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To test the hypothesis that b-chemokine levels may be relevant to
the control of HIV in vivo, we compared RANTES, MIP-1a, and
MIP-1b production from purified CD81 T cells from 81 HIV-infected
subjects and from 28 uninfected donors. Asymptomatic HIV1
subjects produced significantly higher levels of MIP-1a and MIP-1b,
but not RANTES, than uninfected donors or patients that pro-
gressed to AIDS. In contrast, b chemokines in plasma were either
nondetectable or showed no correlation with clinical status. The
high b-chemokine-mediated anti-HIV activity was against the mac-
rophage tropic isolate HIV-1BAL, with no demonstrable effect on
the replication of the T-cell tropic HIV-1IIIB. These findings suggest
that constitutive b-chemokine production may play an important
role in the outcome of HIV-1 infection.
Immune control of HIV-1 infection by CD81 T cells appears tobe mediated in part by HLA class I restricted cytolytic
processes (1). Virus-specific cytotoxic T lymphocytes have been
detected in exposed but uninfected individuals (2, 3). Anti-
HIV-1 cytotoxic T-lymphocyte activity correlates with the down-
regulation of viremia early in infection (4, 5) and with slower
disease progression (6, 7). Further, a strong inverse correlation
was recently described between the frequency of HIV-1-specific
CD81 T cells that bind peptide–MHC tetramers and viral load
for individuals undergoing highly active antiretroviral therapy
(8). The contribution of CD81 T lymphocytes in controlling
viremia is further supported by animal studies (9, 10). CD81 T
lymphocytes can also suppress HIV replication in vitro by a
nonlytic mechanism (11), and this antiviral activity is mediated
by a soluble factor(s) (12, 13).
The noncytolytic antiviral response of CD81 T cells is present
soon after infection and is associated with a decrease in plasma
viremia (14). This antiviral activity has been correlated directly
with the clinical stage of HIV-1 infection (15–17).
In a previous study, we characterized three b chemokines
released by activated CD81 T cells, RANTES, macrophage
inflammatory protein (MIP)-1a, and MIP-1b, as the major
factors responsible for soluble suppressor activity against mac-
rophage tropic HIV-1 isolates (18). It is now established that
RANTES, MIP-1a, and MIP-1b bind to a receptor, CC chemo-
kine receptor 5 (CCR5), that is also required by macrophage
tropic HIV-1 strains as a coreceptor for entry into host cells (19,
20). More recent studies showed this receptor-ligand binding
renders CCR5 unavailable to the virus either by competitively
blocking virus interactions or by causing down-regulation from
host-cell surfaces (21, 22). T-cell tropic HIV-1 isolates are
instead characterized by the usage of another chemokine recep-
tor, CXC chemokine receptor 4 (CXCR4) (23), and the a
chemokine stromal-derived factor 1 (SDF-1), a ligand for
CXCR4, was shown to suppress replication of T-cell tropic
HIV-1 isolates (24, 25). The profound impact of reduced core-
ceptor accessibility on HIV infection in vivo is strongly supported
by evidence that individuals homozygous for a mutant CCR5
allele encoding a fusion-defective molecule (D32) are strongly
resistant to infection (26, 27). Moreover, the heterozygous
condition provides a limited resistance to disease progression
(28, 29).
Collectively, these findings suggest that antiviral immunity
might also be afforded via the release of HIV-suppressive
chemokines from activated CD81 T cells because these chemo-
kines down-regulate CCR5. However, the issue of the effects of
increased production of inhibitory b chemokines in HIV infec-
tion and pathogenesis is still unsettled. In HIV-1-exposed but
-uninfected individuals, an association between overproduction
of b chemokines by CD41 T cells and resistance to in vitro
infection with HIV-1 macrophage tropic isolates has been
described (30). Moreover, in a cohort of uninfected hemophil-
iacs, despite repeated exposure to contaminated blood products,
protection has been associated with the ability of peripheral
blood mononuclear cells (PBMCs) to produce higher levels of
RANTES, MIP-1a, and MIP-1b compared with hemophiliacs
who were never treated with contaminated blood products (31).
A specific immune response involving a high production of b
chemokines by CD41 T cells seems to play a role of protection
in exposed uninfected individuals (32) and may contribute to the
control of viral replication in long-term nonprogressors (33).
Higher b-chemokine secretion by PBMCs has been described in
nonprogressors compared with rapid progressors (34), and
higher production of MIP-1b by PBMCs has been associated
with an asymptomatic status and decreased risk of disease
progression (35). Antigen-induced chemokine production is also
significantly decreased in HIV1 subjects with AIDS compared
with asymptomatic HIV1 subjects (36). In accordance with these
findings, sustained suppression of plasma HIV RNA is associ-
ated with an increase in the production of mitogen-induced
MIP-1a and MIP-1b (37). Moreover, recent results indicate that
human alloimmunization elicits very significant increases in the
three b chemokines RANTES, MIP-1a, and MIP-1b, and re-
sistance of CD41 T cells to HIV infection with macrophage-
tropic HIV-1 strains (38). However, when the production of b
chemokines by unfractionated PBMCs, purified CD41, or CD81
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T cells was examined in small numbers of HIV-1 positive
subjects, the analysis failed to demonstrate any association
between chemokine levels and disease stage (39, 40). Further-
more, plasma levels of b chemokines did not reveal any sub-
stantial differences between progressors and nonprogressors
(41–46). Thus, conclusive evidence for the clinical relevance of
CD81 T-cell b-chemokine-mediated antiviral activity in the
natural history of HIV-1 infection in vivo is still lacking.
To examine this issue, we performed cross-sectional analyses
of RANTES, MIP-1a, and MIP-1b production by purified CD81
T cells from 81 HIV-1-infected subjects at various stages of
disease and from 28 uninfected donors. We analyzed the cor-
relation between b-chemokine production and antiviral activity
in vitro by using the macrophage tropic HIV-1BAL. The effect of
anti-b-chemokine-neutralizing antibodies (NAb) on the CD81
T-cell-mediated antiviral activity was also studied. Moreover, we
determined whether circulating levels of b chemokines reflect
the ability of immunocompetent T cells to produce these mol-
ecules by comparing CD81 T-cell-mediated production with
plasma levels measured in the same blood sample. Additionally,
because of recent reports suggesting the potential for these
chemokines to enhance HIV replication of T-cell tropic HIV-1
strains (47, 48), we determined whether RANTES, MIP-1a, and
MIP-1b produced by activated CD81 T cells could enhance virus
spread of the T-cell tropic HIV-1IIIB by using an acute infectivity
assay. Finally, in this study, we addressed the question of whether
the a-chemokine SDF-1 plays a role in CD81 T-cell-mediated
antiviral activity against the T-cell tropic HIV-1IIIB.
Materials and Methods
HIV-11 Subjects and Control Cases. Heparinized peripheral blood
samples were obtained from HIV-1-infected subjects at different
stages of disease progression. We included 81 HIV-1-infected
subjects in our studies. The only selection criteria were to ensure
that there was representation of patients with AIDS vs. those
without AIDS. All infected cases were being treated with
antiviral drugs at the time of the study. Twenty-eight HIV-1
seronegative blood donors were analyzed for b-chemokine pro-
duction as comparisons. All samples were collected after in-
formed consent (approved by the Institutional Review Board of
the University of Maryland), and by using standard protocols.
In this study, AIDS was defined either by CD41 T-cell count
,200 per ml or by clinical diagnosis (Kaposi’s sarcoma, oppor-
tunistic infection) according to the Center for Disease Control
Criteria (49).
Cell Isolation. PBMCs were obtained from Ficoll-isopaque gra-
dient separation (Amersham Pharmacia). The PBMCs were
washed twice in PBS (Biofluids, Rockville, MD) and resus-
pended in RPMI medium 1640 (GIBCO) containing 10% FCS
(Biofluids), streptomycin (BioWhittaker), and penicillin. CD81
T cells were positively selected by using magnetic beads coated
with monoclonal antibodies against CD8 (Dynabeads; Dynal,
Great Neck, NY) according to the manufacturer’s instructions.
In brief, PBMCs were incubated with beads (10 beads per target
cell) on a rotator for 45 min at 4°C. Rosseted cells were isolated
by placing the tube in a magnetic device (Dynal MPC-6). The
positively selected CD81 T cells were detached from the beads
by using a polyclonal goat anti-mouse Fab reagent (Detacha-
beads; Dynal). Purity of CD81 T cells was routinely .95% as
determined by flow cytometry.
Production of RANTES, MIP-1a, and MIP-1b by Purified CD81 T
Lymphocytes. b-Chemokine production by CD81 T cells was
analyzed after phytohemagglutinin (PHA) (Abbott) stimulation.
The cells were cultured in RPMI 1640 complete medium in the
presence of 1 mgyml of PHA and 10 ngyml of recombinant
human IL-2 (Rh IL-2) (R & D Systems) at a cell concentration
of 2 3 106 cells per ml. After 3 days of PHA stimulation of the
culture, supernatants were collected and stored frozen at 270°C
until analyzed for b-chemokine levels by ELISA (Quantikine
Kits, R & D Systems) according to the manufacturer’s instruc-
tions. The b-chemokine response to PHA was highly reproduc-
ible within 10% in randomly selected samples where we repeated
the analysis three times at weekly intervals. In parallel, we also
measured plasma levels.
Production of SDF-1 by Purified CD81 T Lymphocytes. The CD81 T
cells were cultured in RPMI 1640 complete medium in the
presence of 1 mgyml of PHA and 10 ngyml of Rh IL-2 at a cell
concentration of 2 3 106 cells per ml. After 3 days of PHA
stimulation, the culture supernatants were collected and
stored frozen at 270°C until analyzed for SDF-1 levels by
ELISA. ELISA was performed by microQuant Service Lab-
oratory, Institute of Human Virology, as previously described
(50), except ELISA plates were coated with polyclonal goat
antibody directed against recombinant SDF-1a (Santa Cruz
Biotechnology).
Virus Suppression Assay. We used an acute infection assay because
it allowed us to evaluate the CD81 T-cell response among
different individuals by using different HIV-1 strains. PBMCs
from a normal donor previously activated with PHA (1 mgyml)
for 3 days were acutely infected with HIV-1–1BAL or HIV-1–
1IIIB, by using the same titer for both viruses (multiplicity of
infection 5 0.01) for 1 h at 37°C. Cells were washed twice with
PBS to remove unabsorbed virus and resuspended in complete
RPMI medium containing Rh IL-2 (10 ngyml). After infection,
PBMCs were cultured in the presence or absence of CD81
T-cell-free supernatants obtained from HIV-1 subjects (50%
volyvol). Duplicate cultures were established with 1 3 105 cells
per well in 96-well f lat-bottom microtiter plates. Every 2 days,
half of the medium was replaced with fresh medium or cell-free
supernatants from activated CD81 T cells. The supernatant from
the cultures was harvested at day 8 after infection and tested for
HIV-1 replication by p24 ELISA (Du Pont).
Statistical Analysis. Descriptive statistics were generated by using
Statistical Package for the Social Sciences. Analysis was con-
ducted by using parametric and nonparametric methods where
appropriate after assessment for normalcy. Relationships be-
tween continuous variables were assessed by using the Pearson
correlation coefficient or its nonparametric equivalent, Spear-
man’s rank coefficient. For categorical independent variables,
differences between groups were assessed by using Student’s t
tests or analysis of variance, or nonparametric tests, including the
Mann–Whitney and the Kruskal–Wallis tests. For dependent
observations (measured on the same sample), we used the t test
or the nonparametric alternative, Wilcoxon’s matched-pairs test.
Activated CD81 T cells mediate HIV-1 suppression via sol-
uble factors. Levels of this activity appear to decrease with the
progression of HIV-1 infection. In view of the large body of
evidence showing that RANTES, MIP-1a, and MIP-1b are
major components of this activity, we evaluated the potential
clinical relevance of these b chemokines in HIV-1 infection.
Results
Higher MIP-1a and MIP-1b Production by CD81 T Cells from HIV-
Infected Individuals Correlates with Better Clinical Status. The pro-
duction of RANTES, MIP-1a, and MIP-1b by CD81 T cells
obtained from HIV-1-infected individuals was assayed by
ELISA 72 h after activation with PHA and IL-2. The data were
then grouped and compared to determine whether chemokine
production varies significantly in association with certain clinical
profiles. The data were first grouped according to whether the
CD41 T-cell counts of the donors were less than (Group A, n 5






























34) or greater than (Group B, n 5 47) 200 cells per ml. A CD41
T-cell count of 200 per ml or less is an accepted criterion for
diagnosis of AIDS (49). CD81 T cells obtained from uninfected
donors were also analyzed to provide a third data group (Group
C, n 5 28) for further comparisons. As shown in Fig. 1, the mean
secreted levels of MIP-1a and MIP-1b in Group B were signif-
icantly higher than observed with either Group A [MIP-1a (P 5
0.004); MIP-1b (P 5 0.008)] or Group C [MIP-1a (P 5 0.012);
MIP-1b (P 5 0.001)]. In contrast, there were no significant
differences in the mean levels of these chemokines between
groups A and C. Thus, higher production of MIP-1a and MIP-1b
was associated with HIV1 donors demonstrating higher CD41
T-cell counts. In contrast to MIP-1a and MIP-1b, mean
RANTES levels were not significantly different among the
three subject groups.
The relationship between chemokine production and CD41
T-cell count in HIV1 individuals was further studied by Pearson
analysis (Table 1). In accordance with the previous analyses (Fig.
1), a significant linear correlation was evident between CD41
T-cell count and production of MIP-1a (r 5 0.266, P 5 0.017)
and MIP-1b (r 5 0.293, P 5 0.008). Notably, a correlation was
also found between MIP-1a (r 5 0.343, P 5 0.002) and MIP-1b
(r 5 0.310, P 5 0.006) production and peripheral blood CD81
T-cell count. Again, there was no significant correlation between
RANTES production and CD41 and CD81 T-cell counts.
The data were also grouped according to whether the HIV-
infected donors were clinically diagnosed with AIDS based on
Kaposi’s sarcoma or opportunistic infection. As shown in Fig. 2,
mean MIP-1a and MIP-1b production was significantly higher
with activated CD81 T cells from HIV-1-infected individuals
who remain clinically asymptomatic as compared with those with
a clinical diagnosis of AIDS [MIP-1a (P 5 0.035); MIP-1b (P 5
0.016)]. As in the previous analyses, there was no significant
association between mean RANTES production among the
HIV1 subject groups.
b-Chemokine Levels in CD81 T Cell Supernatants Suppress Macro-
phage Tropic Viruses but Do Not Enhance Replication of T Tropic
Viruses. We evaluated the relationship between the b-chemokine
levels and the ability of cell-free supernatants from 48 subjects
to inhibit the macrophage tropic HIV-1BAL or the T-cell tropic
HIV-1IIIB. However, because of lack of supernatants, only 21
subjects were evaluated by using T-cell tropic HIV-1IIIB. The
effect of cell-free supernatants obtained from PHA-stimulated
purified CD81 T cells was tested for the antiviral activity in in
vitro infected mitogen-activated primary PBMCs system. The
PBMCs were cultured in the presence or absence of CD81
Fig. 1. Comparison of b-chemokine production by CD81 T cells from HIV-1-
infected cases stratified by CD41 T-cell count and uninfected cases. CD81 T cells
were isolated from HIV1 individuals with CD41 T-cell counts less than (Group
A) or greater than (Group B) 200 cells per ml. CD81 T cells were also obtained
from uninfected donors (Group C) for further comparisons. The cells were
isolated from freshly collected PMBCs by immunomagnetic beads, and 2 3 106
cells per ml were activated with PHA (1 mgyml) and Rh IL-2 (10 ngyml).
b-Chemokine production by CD81 T cells was analyzed in the culture super-
natants after 3 days of PHA stimulation by ELISA. The indicated p-values were
generated from t tests. For analyses of MIP-1a: *, P 5 0.012, #, P 5 0.004. For
analyses of MIP-1b: *, P 5 0.001, #, P 5 0.008. The differences in RANTES values
were not significant. Bars indicate the standard errors of the means.
Table 1. Relationship between lymphocyte subsets and b-chemokine production from CD81 T cells and matched
plasma
Plasma CD81 T cells
RANTES MIP-1a MIP-1b RANTES MIP-1a MIP-1b
CD4 count
Pearson correlation 2.160 .317 .027 .014 .266 .293
Sig. (2-tailed) .225 .011 .829 .901 .017 .008
N 59 64 64 81 81 81
CD8 count
Pearson correlation 2.144 .358 .136 .040 .343 .310
Sig. (2-tailed) .293 .005 .301 .734 .002 .006
N 55 60 60 76 76 76
Maximum number, 81 HIV-1 cases; lower numbers reflect missing data; Sig., significant; N, number of samples.
Fig. 2. Lower production of MIP-1a and MIP-1b by CD81 T cells from HIV-11
individuals with clinical diagnosis of AIDS defined by CDC criteria compared
with asymptomatic subjects. CD81 T cells were isolated from HIV1 individuals
who were clinically asymptomatic or diagnosed with AIDS based on Kaposi’s
sarcoma or opportunistic infection. The cells were isolated, cultured, and
analyzed as described in Fig. 1 and in the text. The indicated p-values were
generated from t tests. For analyses of MIP-1a: P 5 0.035 or MIP-1b: P 5 0.016.
The difference in RANTES values was not significant. Bars indicate the stan-
dard errors of the means.




















T-cell-free supernatant (50% volyvol). The antiviral effect was
determined by the extent of inhibition of viral replication relative
to results with PBMCs cultured alone. Our analysis demon-
strated a correlation between b-chemokine production and
inhibition of HIV-1BAL (r 5 0.340, P 5 0.018). As illustrated in
Fig. 3, pretreatment with polyclonal goat IgG NAb against
RANTES, MIP-1a, and MIP-1b completely reversed the sup-
pressive activity secreted by primary CD81 T cells in four of the
eight HIV1 subjects tested, whereas in the other four patients,
the antiviral activity was neutralized between 70 and 80%. On
the contrary, and in agreement with our previous results, there
was no correlation between the levels of these molecules and the
antiviral activity against HIV-1IIIB (18). Nevertheless, b-chemo-
kine levels in CD81 T-cell supernatants had no effect on
replication of HIV-1IIIB as measured by p24 antigen by ELISA
(data not shown).
Role of the Antiviral Chemokine SDF-1 in the CD81 T-Cell-Mediated
Antiviral Activity. The production of the a-chemokine SDF-1 by
CD81 T cells obtained from 21 HIV-1-infected individuals was
tested by ELISA 72 h after PHA and IL-2 stimulation. Our
analyses revealed very low levels of this chemokine (,0.5 ngyml,
data not shown). Consistent with this finding, when we examined
the association between SDF-1 levels and the ability of cell-free
supernatants from CD81 T cells to inhibit the T-cell tropic
HIV-1IIIB, our analyses demonstrated a lack of correlation (data
not shown).
Lack of Relationship Between Plasma Levels of RANTES, MIP-1a,
MIP-1b, and Clinical Status. We examined the association between
plasma levels of RANTES, MIP-1a, and MIP-1b and clinical
status in the same cohort of HIV1 individuals. We also examined
whether b-chemokine production by PHA-stimulated CD81 T
cells correlates with plasma levels measured in the same samples.
Our results did not reveal any association between plasma levels
of RANTES, MIP-1a, and MIP-1b and clinical status (data not
shown). Of interest, when the relationship between plasma levels
of RANTES, MIP-1a, and MIP-1b and cell production of this
chemokine was examined, the analysis did not reveal a correla-
tion between plasma levels and the ability of CD81 T cells to
release these molecules after in vitro activation (data not shown).
However, as illustrated in Table 1, plasma levels of MIP-1a
correlated with both CD41 T-cell count (r 5 0.317, P 5 0.011)
and CD81 T-cell count (r 5 0.358, P 5 0.005). On the contrary,
RANTES and MIP-1b production did not correlate with either
CD41 or CD81 T-cell count.
Discussion
Activated CD81 T cells have been characterized as major sources
of a soluble noncytolytic HIV-suppressive activity (12, 13).
Consequently, numerous studies have been carried out to ex-
amine how the production of this activity in response to non-
specific activation by mitogen or anti-CD3 antibody changes
during disease progression in HIV-infected persons (15–17).
Despite the establishment of RANTES, MIP-1a, and MIP-1b as
major mediators of this activity, and that in terms of T lympho-
cytes CD81 T cells are a more potent source of b chemokine
(51), there is still no conclusive evidence for the role of CD81
T-cell b-chemokine-mediated anti-HIV responses in HIV-1
pathogenesis. To address this issue, we performed a cross-
sectional study of freshly isolated CD81 T cells from 81 sero-
positive patients at different stages of infection along with 28
healthy controls to evaluate differences in chemokine release
after nonspecific activation in vitro. Analysis of the data has
demonstrated that MIP-1a and MIP-1b production by CD81 T
cells from asymptomatic HIV-11 subjects was substantially
greater than production observed in uninfected donors. In
contrast, no significant difference in RANTES production was
observed. The activation of CD81 T cell subsets after exposure
to HIV-1 antigens might be responsible for the increased
b-chemokine production observed in asymptomatic HIV-11
individuals. This may represent a specific anti-HIV immune
response, which plays a role in viral control. This hypothesis is
supported by recent studies where HIV-1-specific CD81 T cells
have been shown to synthesize the b-chemokine RANTES,
MIP-1a, and MIP-1b along with cytolytic activity (52).
In this study, we demonstrated that the mean levels of MIP-1a
and MIP-1b released by CD81 T cells are significantly lower
among HIV1 persons with AIDS as defined by CD41 T-cell
counts below 200 per ml or by the clinical diagnosis compared
with asymptomatic HIV1 subjects. Moreover, MIP-1a and
MIP-1b production by CD81 T lymphocytes correlated with
CD41 and CD81 T-cell counts.
These findings suggest that activated CD81 T cells may
represent an important source of MIP-1a and MIP-1b in vivo.
The neutralization of CD81 T-cell-mediated antiviral activity in
assay with macrophage-tropic HIV-1 isolates after pretreatment
with NAb to RANTES, MIP-1a, and MIP-1b indicated that the
levels of chemokines released in vitro are sufficient to suppress
HIV and represent the major component of the anti-HIV
activity, thus suggesting the potential role of these molecules in
controlling HIV replication in vivo. The increase in CD81 T-cell
b-chemokine-mediated anti-HIV-1 effects may result in greater
antiviral activity and consequentially contribute to slower pro-
gression. The association between high levels of MIP-1b pro-
duction by activated CD81 T cells and the asymptomatic status
reported here is consistent with its specificity for the CCR5
coreceptor (53). Because MIP-1b is less promiscuous than
MIP-1a or RANTES and may bind solely to CCR5, high levels
of this chemokine may suppress HIV-1 more efficiently.
The decreased ability of CD81 T lymphocytes to produce
MIP-1a and MIP-1b in HIV-11 subjects who developed AIDS
may contribute to less sustained suppression of HIV-1 replica-
tion that contributes to ultimate disease development. HIV-1
disease progression is not necessarily associated with virus
insensitivity to the b-chemokine effect (54, 55), because 50% of
the HIV-11 subjects who developed AIDS harbor nonsyncytia
inducing viruses (56). The loss of viral control in these patients,
Fig. 3. The effect of anti-b chemokine NAb on the CD81 T-cell-mediated
antiviral activity against the macrophage tropic HIV-1BAL. The CD81 T-cell
culture supernatants obtained from 8 HIV1 subjects were assayed for antiviral
activity in the presence of either a nonspecific control antibody (300 mgyml)
(■) or a mixture of NAb specific to RANTES (100 mgyml), MIP-1a (100 mgyml),
and MIP-1b (100 mgyml) (o). The neutralization test was performed by incu-
bating the antibody (R & D Systems) for 30 min at room temperature. Anti-
bodies were added at the initiation of the culture and were replaced after 48 h
on medium exchange. The effect on HIV replication was determined at day 8
by p24 ELISA.






























independent of the sensitivity of their primary isolates to the
antiviral effect of the recombinant b chemokine in vitro (54, 55),
might instead reflect a decreased ability of the CD81 T cells to
produce the antiviral b-chemokine MIP-1a and MIP-1b.
Because the release of other HIV-suppressive chemokines (24,
25, 57) and perhaps other soluble antiviral factors yet to be
identified may also contribute to the inhibition of HIV infection
(58), we investigated the potential role of the antiviral chemokine
SDF-1 in the CD81 T-cell-mediated antiviral activity against T-cell
tropic HIV-1 strains. Our results indicated that SDF-1 is unlikely
involved in the CD81 T-cell-mediated antiviral activity against
T-cell tropic HIV-1, in agreement with a previous report showing
extremely low levels of SDF-1 mRNA transcript in CD81 T cells
and a lack of correlation between these levels and the CD81
T-cell-mediated suppressive activity (59).
In contrast to the results with cells, we found no difference in
plasma levels of RANTES, MIP-1a, and MIP-1b between HIV1
subjects differentiated by CD41 T-cell counts. Moreover, our
analysis demonstrated a lack of correlation between CD41 and
CD81 T-cell counts and plasma levels of MIP-1b or RANTES,
although a statistically significant correlation was observed with
MIP-1a. Given that chemokines aggregate, adhere to extracellular
carbohydrates, and arise from platelets during sample collection
(60, 61), these results should not be surprising. Indeed, our analysis
showed no correlation between plasma levels of b chemokines and
the ability of CD81 T cells to release these molecules. These data
underscore the inherent inaccuracies in plasma chemokine mea-
surements, suggesting that circulating levels are unlikely to reflect
what is present at the immune effector sites, and probably explain
why such studies failed to demonstrate any association between
chemokine levels and disease stage (41–46).
Our data demonstrated that in a cross-sectional analysis,
higher production of MIP-1a and MIP-b by CD81 T lympho-
cytes is associated with better clinical status. A statistically
significant correlation was detected between suppression of the
macrophage tropic HIV-1BAL and b-chemokine levels produced
by activated CD81 T cells; moreover, NAb to RANTES, MIP-
1a, and MIP-1b were able to reverse the suppressive activity.
These chemokine levels, although sufficient for suppression of
the macrophage tropic HIV-1BAL, played no role in enhancing
the replication of the T-cell tropic HIV-1IIIB. This effect appar-
ently involves receptor activation and stimulation of colocaliza-
tion of CD4 and CXCR4 that facilitate more efficient viral entry
(62). Our data suggest that it is unlikely that the physiologic
levels of these molecules produced in vivo could play a role in
enhancing the replication of T-cell tropic HIV-1.
Future longitudinal studies to elucidate the mechanism of
these effects should identify CD81 T-cell subsets that can be
activated by mitogen to secrete MIP-1a and MIP-1b to charac-
terize which changes in CD81 T cells ultimately cause the
reduction in chemokine release. There may be selective loss of
a subset that gives rise to chemokine-secreting effector cells or
progressive impairment in chemokine production on a per cell
basis, which occur with AIDS development.
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